Chromadex director Caroline Levy resigns from board and committees

Niagen Bioscience, Inc.

Levy resigned effective April 11, 2022; no disagreement with the company cited.
She also stepped down from the Audit Committee and Nominating and Corporate Governance Committee.
No replacement or interim appointment announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Caroline Levy

Director

NAGE · Niagen Bioscience, Inc.

Effective: 2022-04-11
Filed: April 15, 2022, 7:59 PM ET

On April 11, 2022, Caroline Levy notified the Company of her intention to resign from the Board and as a member of the Audit Committee and Nominating and Corporate Governance Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Caroline Levy resigned as Director at Niagen Bioscience, Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 11, 2022, Caroline Levy notified the Company of her intention to resign from the Board and as a member of the Audit Committee and Nominating and Corporate Governance Committee of the Board.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-009372

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.